HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO IVF Hospital Management Group - The Industry, the Business and the Risks Behind

Pre-IPO Numans Health Food Holdings - Due to Flawed Business Model, Future Growth Is Uncertain

Will China TCM (570.HK) Be Incorporated into Taiji Group (600129.CH)? –If Yes, Valuation Will Double

China Healthcare Weekly (Dec.15)-BMS/Biokin $8.4B Eye-Popping Deal, NRDL Negotiation Result, Haoyuan

Pfizer Inc (PFE.US) - What if Pfizer Loses the China Market in the Future?

WuXi AppTec (2359.HK/603259.CH) - How Bad Things Could Be?

Pre-IPO HighTide Therapeutics (PHIP Updates) - Some Shareholders Have Chosen to Quit in Advance

Equity Bottom-Up

<ul>
<li>Pfizer seems to be the worst-performing large pharma stock of 2023 after it lowered 2024 forecast. The Company continues to grapple with plummeting demand for its COVID products</li>
<li>The acquisition of Seagen can't turn things around. Except a few products that are still able to maintain growth, sales of vast majority products that we’re familiar with are declining. </li>
<li>The growth engine of Pfizer in post-pandemic era is still uncertain. Even though Pfizer's share price has fallen sharply, this may still not be the time for bottom fishing.</li>
</ul>


Pfizer seems to be the worst-performing large pharma stock of 2023 after it lowered 2024 forecast. The Company continues to grapple with plummeting demand for its COVID products
The acquisition of Seagen can't turn things around. Except a few products that are still able to maintain growth, sales of vast majority products that we’re familiar with are declining. 
The growth engine of Pfizer in post-pandemic era is still uncertain. Even though Pfizer's share price has fallen sharply, this may still not be the time for bottom fishing.


화이자(PFE US) - 팬데믹 이후 시대에도 계속 길을 잃다